Genomic Health eyes wider breast cancer market for Oncotype DX test
This article was originally published in Clinica
Executive Summary
Moving towards expanding the indication of Genomic Health's Oncotype DX breast cancer recurrence test, a study has shown that the assay is also effective in patients with higher-risk, node-positive breast cancer.